XML 11 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue:    
Total revenue $ 143,537 $ 96,850
Cost of revenue:    
Total cost of revenue 55,309 36,888
Gross profit 88,228 59,962
Operating expenses:    
Research, development and clinical trials 17,160 11,380
Selling, general and administrative 43,625 36,161
Total operating expenses 60,785 47,541
Income from operations 27,443 12,421
Other income (expense):    
Interest expense (3,461) (3,598)
Interest income and other income (expense) 2,694 3,570
Total other expense, net (767) (28)
Income before income taxes 26,676 12,393
Provision for income taxes (994) (196)
Net income $ 25,682 $ 12,197
Net income per share, basic $ 0.76 $ 0.37
Net income per share, diluted $ 0.7 $ 0.35
Weighted average common shares outstanding, basic 33,721,603 32,760,190
Weighted average common shares outstanding, diluted 39,914,487 34,678,895
Net product revenue [Member]    
Revenue:    
Total revenue $ 88,234 $ 61,325
Cost of revenue:    
Total cost of revenue 16,312 14,084
Service Revenue [Member]    
Revenue:    
Total revenue 55,303 35,525
Cost of revenue:    
Total cost of revenue $ 38,997 $ 22,804